The rise of Sildenafil initially fueled a boom for pharma, but recent developments present a murky picture for shareholders. Off-patent competitors are eroding profits, and ongoing litigation add more risk to the landscape. While certain companies might still benefit from complementary offerings, the broader trajectory suggests a measured approach